EyeGate Pharmaceuticals Inc buy melinda
Start price
17.11.18
/
50%
€6.50
Target price
28.11.18
€0.90
Performance (%)
14.58%
End price
28.11.18
€7.44
Summary
This prediction ended on 28.11.18 with a price of €7.44. The prediction had a final performance of 14.58%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| EyeGate Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
| iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
| iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
| iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by melinda for this prediction
In the thread EyeGate Pharmaceuticals Inc diskutieren
Eyegate Pharmaceuticals (EYEG) PT Set à 6,00 $ par HC Wainwright
Develops pharmaceutical products to treat eye diseases
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel (OBG).
OBG is a topically-applied eye drop formulation that is being developed under the 510k De Novo path for devices submitted for marketing clearance to the U.S. FDA. The company was founded in 1998 and is headquartered in Waltham, MA.
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel (OBG).
OBG is a topically-applied eye drop formulation that is being developed under the 510k De Novo path for devices submitted for marketing clearance to the U.S. FDA. The company was founded in 1998 and is headquartered in Waltham, MA.
Nombre d'employés : 17 personnes.
Stopped prediction by melinda for EyeGate Pharmaceuticals Inc
EyeGate Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€17.26
14.06.17
14.06.17
€1.58
14.12.17
14.12.17
-4.59%
14.12.17
14.12.17
EyeGate Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€26.65
01.05.17
01.05.17
€2.26
22.05.17
22.05.17
4.03%
22.05.17
22.05.17